A detailed history of California State Teachers Retirement System transactions in Erasca, Inc. stock. As of the latest transaction made, California State Teachers Retirement System holds 160,436 shares of ERAS stock, worth $450,825. This represents 0.0% of its overall portfolio holdings.

Number of Shares
160,436
Previous 8,172 1863.24%
Holding current value
$450,825
Previous $19,000 2200.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.17 - $3.28 $330,412 - $499,425
152,264 Added 1863.24%
160,436 $437,000
Q2 2024

Aug 14, 2024

BUY
$1.79 - $2.63 $105 - $155
59 Added 0.73%
8,172 $19,000
Q1 2024

May 15, 2024

SELL
$1.67 - $2.55 $120,659 - $184,240
-72,251 Reduced 89.9%
8,113 $16,000
Q4 2023

Feb 13, 2024

SELL
$1.67 - $2.49 $17,872 - $26,647
-10,702 Reduced 11.75%
80,364 $171,000
Q3 2023

Nov 14, 2023

SELL
$1.97 - $2.91 $3,955 - $5,843
-2,008 Reduced 2.16%
91,066 $179,000
Q2 2023

Aug 21, 2023

BUY
$2.57 - $3.3 $14,934 - $19,176
5,811 Added 6.66%
93,074 $256,000
Q1 2023

May 09, 2023

BUY
$2.74 - $4.44 $4,562 - $7,392
1,665 Added 1.95%
87,263 $262,000
Q4 2022

Feb 14, 2023

BUY
$3.89 - $8.57 $131,404 - $289,494
33,780 Added 65.19%
85,598 $368,000
Q3 2022

Nov 18, 2022

SELL
$5.82 - $10.68 $10,691 - $19,619
-1,837 Reduced 3.42%
51,818 $404,000
Q2 2022

Aug 15, 2022

BUY
$4.58 - $8.72 $24,104 - $45,893
5,263 Added 10.88%
53,655 $299,000
Q1 2022

May 16, 2022

BUY
$8.6 - $15.48 $143,843 - $258,918
16,726 Added 52.82%
48,392 $416,000
Q4 2021

Feb 15, 2022

BUY
$12.51 - $22.75 $256,392 - $466,261
20,495 Added 183.47%
31,666 $493,000
Q3 2021

Nov 15, 2021

BUY
$17.43 - $24.34 $194,710 - $271,902
11,171 New
11,171 $237,000

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $343M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track California State Teachers Retirement System Portfolio

Follow California State Teachers Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California State Teachers Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California State Teachers Retirement System with notifications on news.